You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Express Scripts

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 7,642,234

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,642,234
Title:Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
Abstract: The present disclosure provides a method of inhibiting angiogenesis within a tissue of interest by providing either intact or nicked .beta.-Glycoprotein 1 (.beta.2GP1) to cells associated with the tissue. The presence of .beta.2GP1 inhibits angiogenesis within the tissue, in part by preventing neovascularization into the tissue. The disclosure also provides a method for treating tumors by providing .beta.2GP1 to the tumor.
Inventor(s): Schroit; Alan Jay (Bellaire, TX), Balasubramanian; Krishnakumar (Pearland, TX), McCarty; Marya F. (Bellaire, TX)
Assignee: Board of Regents The University of Texas Systems (Austin, TX)
Application Number:11/810,521
Patent Claims:see list of patent claims

Details for Patent 7,642,234

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Board of Regents The University of Texas Systems (Austin, TX) 2039-03-29 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Board of Regents The University of Texas Systems (Austin, TX) 2039-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,642,234

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Merck
Mallinckrodt
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.